Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx
Phase 2
1 Year
N/A
1 Year
N/A
Open (Enrolling)
Both
Precancerous Condition
Both
Precancerous Condition
Trial Information
Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the
larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously
weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
Inclusion Criteria
DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx
requiring surgery at least 4 times per year Condition must have existed for more than 1
year
PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life
expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
specified
PRIOR CONCURRENT THERAPY: See Disease Characteristics
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Principal Investigator
James M. Oleske, MD
Investigator Role:
Study Chair
Investigator Affiliation:
University of Medicine and Dentistry New Jersey
Authority:
United States: Federal Government
Study ID:
CDR0000071657
NCT ID:
NCT00002454
Start Date:
December 1971
Completion Date:
Related Keywords:
- Precancerous Condition
- lung papilloma
- Papilloma
- Precancerous Conditions
Name | Location |
|---|---|
| New Jersey Medical School | Newark, New Jersey 07103-2714 |
